Gimenez Arnau News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gimenez Arnau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gimenez Arnau Today - Breaking & Trending Today

Novartis Pharma AG: Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)

Published: December 20, 2021

Ad hoc announcement pursuant to Art. 53 LR Ligelizumab, a high-affinity anti-IgE antibody, demonstrated superiority compared with placebo at Week 12 in Phase III PEARL 1 and PEARL 2 trials, but not

Source: finanznachrichten.de

Related Topics:

United StatesIsabella ZinckFerrerm UpdosingMichael MeoThomas HungerbuehlerLouise ClarkSamir ShahGimenez ArnauParag MahantiJulie MasowSloan SimpsonJohn TsaiAlina LevchukExchange CommissionNovartis Global CommunicationsHead Of Global Drug DevelopmentGlobal Urticaria ForumNovartis Us External CommunicationsGlobal Drug DevelopmentChief Medical OfficerUrticaria Activity ScoreAdv ChronicSpontaneous UrticariaAllergy Asthma ImmunolAdults Inadequately Controlled